Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new antibody drug, rozanolixizumab, showed only modest benefits for severe fibromyalgia patients in a phase 2A trial. While it meaningfully improved overall fibromyalgia impact scores, it failed to significantly reduce pain intensity or fatigue. Researchers say larger, more diverse trials are needed before drawing firm conclusions.
Rozanolixizumab, an antibody that targets the neonatal Fc receptor for IgG, was put to the test in a phase 2A randomized, placebo-controlled trial involving 63 adults with severe fibromyalgia. The drug showed a statistically meaningful improvement in overall fibromyalgia impact — but fell short on the primary endpoint of pain interference at the standard two-sided significance level, and showed no benefit for pain intensity or fatigue.
The trial, conducted across seven sites in England, randomly assigned participants to receive the drug weekly for 24 weeks, a crossover regimen, or placebo. Notably, the drug reduced total IgG levels by ~60% within four weeks — a key mechanism of action — and was generally well tolerated with few serious adverse events.
By the Numbers:
Why it matters: Fibromyalgia remains notoriously difficult to treat, with few effective options. While rozanolixizumab's results are mixed, the significant improvement in overall disease impact hints at a potential new immunological pathway worth exploring — pending larger, more diverse trials.
